Early Experiences with Stem Cells in Treating Chronic Wounds

https://doi.org/10.1016/j.cps.2012.04.005Get rights and content

Introduction

The wound healing process contains well-organized and integrated patterns of complex biologic, molecular, and gene involvement events of

  • Cell proliferation

  • Cell migration

  • Differentiation capacity of cells

  • Extracellular matrix (ECM) deposition and degradation.

Within seconds, minutes, and hours after injury, epidermal and dermal cell migration, proliferation, and differentiation initiate re-epithelialization.1 External injury may trigger tissue hypoxia, which leads to upregulation of local growth factors (cytokines), degradation of ECM, and may ultimately lead to angiogenesis. Newly formed granulation tissue must be sustained to establish the formation of new blood vessels.2 Many diseases are related to keratinocyte or epidermal cell loss, angiogenesis dysfunction, and incomplete skin regeneration. These disorders including Buerger disease, chronic radiation wounds, and other chronic wound healing problems are under clinical investigation for possible new therapeutic modalities. Autologous adipose-derived stem cells (ADSCs) show great promise as an adjunct in facilitating the healing of these complex wounds.

Wound healing in skin comprises 4 major distinctive, but overlapping phases:

  • 1.

    Hemostasis

  • 2.

    Inflammatory

  • 3.

    Proliferation

  • 4.

    Remodeling.

In a chronic wound, remarkable changes related to senescence, ischemia, matrix biology, and bacterial colonization transform the normal progression of wound healing into a self-continuing cycle of inflammation and injury.3 Injured tissue induces tissue hypoxia, which leads to upregulation of growth factors; degradation of ECM activates local angiogenesis. Stem cells have shown to promote angiogenic processes.4, 5, 6 Stem cells also may be differentiated into various cells including fibroblasts, which are major component of dermis.7

Chronic wounds include venous ulcers, pressure ulcers, and diabetic ulcers, which may account for 90% of all nonhealing wounds.3

Venous ulcers are highly prevalent in woman8 and are related to circulatory insufficiency and venous hypertension located in and around the malleolus.

Pressure sores commonly occur in patients with impaired mobility and under prolonged medical and surgical care, such as extensive surgery, time spent in an intensive care unit, and poor systemic nutrition status. Pressure ulcers arise from external force, friction, and shear forces that affect segmental and perforator arteries leading to tissue necrosis particularly over bony prominences.9

Diabetic ulcers result in long-term complications in diabetic patients. Most ulcers in patients with diabetes are located in pressure points of the foot and can arise from peripheral neuropathy, foot deformity, and local minor trauma.10 In a diabetic wound, ischemia can result from a macrovascular, microvascular, and neuropathic disease, or all the aforementioned.11

Chronic wounds are complicated and etiologically multifactorial. Ischemia-reperfusion injury may play a major and important role in etiology.3 Ischemic stresses are altered in elderly people, partly because of the combination of ischemia and oxidant stresses in the ischemia-reperfusion injury.12 Negative pressure wound therapy may prevent systemic damage caused by ischemic reperfusion, as demonstrated in a pig model.13

Wound healing contains multifactorial local and systemic factors. Wound bed preparation involves management of the following parameters14:

  • Tissue viability

  • Involvement of infection

  • Moisture balance

  • Wound edges.

In addition, local alteration of metalloproteinases, integrins, chemokines, and growth factors on the wound surface must be controlled.15, 16, 17

Treatment of chronic wounds is affected by optimal environmental conditions, the healing process, and subsequent scarring. Surgical or nonsurgical debridement, reduction of edema, diminishing bacterial burdens, maintaining the favorable moisture balance, and removal of undermining tissues are included in standard wound care.18

Wound characteristics can be modified with a variety of recently developed topical dressings such as impregnated gauze, film, hydrogel, hydrocolloid, and alginate. Advanced therapies include mechanical devices providing topical negative pressure and bioengineered tissues of various types.19, 20, 21, 22, 23 Even though vigorous development of such materials, devices, and products are underway, surgical debridement is still required to facilitate wound healing. Debridement can reduce the bioburden of a wound selectively and effectively. Necrotic tissue, which must be eliminated because it behaves as a substrate for proliferating bacteria that strives for the same nutrients and oxygen molecules essential for wound healing, is best removed with debridement.

Stem cells are able to24

  • Undergo self-renewal

  • Be cell proliferative

  • Differentiate into multiple lineages of cell and tissue phenotypes.

Recent technological developments now allow isolation and culture of stem cells, which has enabled researchers to perform vigorous studies on somatic or adult stem cells.

Adult stem cells can differentiate into adipogenic, osteogenic, and neurogenic cell types.25 The autologous adult stem cells are readily available from the patient, thus not affected by ethical and immunologic barriers. Mesenchymal stem cells are first isolated from bone marrow and extend to almost all organs and tissues.26, 27 Bone marrow-derived stem cells (BMMSCs) from a single donor can differentiate into liver epithelium, lung, gastrointestinal tract, and skin.28, 29 BMMSCs are relatively easily obtained from bone-marrow aspirates of donor patients. BMMSCs are isolated and expanded in vitro by subculturing.30 Human BMMSCs (hBMMSCs) are resistant to 20 Gy radiation in vitro; immediately after exposure to 20 Gy radiations and reconstruction with hBMMSCs and angiogenic growth factor (basic fibroblast growth factor, [bFGF]), artificial dermis demonstrated improved wound healing in 10 days.31

Case 1: Procedural radiation injury

A 58-year-old male patient had received 45 Gy of radiation and subsequently developed chest pain. He then underwent percutaneous transluminal coronary angioplasty under fluoroscopy, which was unexpectedly prolonged as a result of intraoperative complications. Immediately after the procedure, the patient noticed strong, deep, penetrating pain in his back. He subsequently developed a localized wound deep into the costal cartilage and a surrounding erythematic lesion, which was apparent at first follow-up surgical visit. The wound was widely excised including the necrotic cartilage and was reconstructed with a bilobed latissimus dorsi musculocutaneous flap. The scar tissue resulting from exposure to original radiation was further analyzed via histologic analysis. Small spindle-shaped cells were concentrated within the fibrotic tissue and Stro-1, which is one of the immunoreactive markers of mesenchymal stem cells.32 This finding suggested that stem cells may mediate a radiation injury (Fig. 1).

BMMSCs can synthesize higher amount of collagen, fibroblast growth factor (FGF), and vascular endothelial growth factor (VEGF), suggesting a potential benefit in accelerating wound healing.33 hBMMSCs are able to accelerate wound healing with a collagen sponge with bFGF.34 Over a 1-year observation of autologous bone marrow cell treatment for 3 nonhealing wounds, which previously failed to heal with the use of bioengineered skin or skin grafting, complete closure and dermal rebuilding in all cases was demonstrated with autologous bone marrow cell. Reduced scarring and engraftment of grafted cells was observed.35 Fibrin polymer spray, in which fibrinogen contains cultured autologous BMMSCs, can adhere to the wound bed and retain the cell viability and migration.36 Cultured BMMSCs are used for severe radiation-associated wounds with numerical dosimetry-guided surgery followed up to 11 months.37 Also, cultured BMMSCs are effective for intractable wounds when soaked in an artificial dermis.38 In addition, direct injection of cultured BMMSCs into the wound area in normal diabetic mice promoted wound healing through the release of proangiogenic factors on differentiation39; In streptozocin (STX)-induced diabetic rats, BMMSC double-system injections through the tail vein and local injection at the wound site augmented growth factors such as EGF, VEGF, platelet-derived growth factor-BB markedly and transforming growth factor-β and keratinocyte growth factor (KGF) moderately.40, 41 BMMSCs induce potent differentiation and proliferation under low oxygen tension with cell morphologic and cell cycle changes and differentiation capacity toward bone and fat.42

Furthermore, hBMMSCs transplantation to an adult rabbit incisional wound demonstrated tensile strength 80 days after surgery.43 Systemic administration of rat BMMSCs for 4 days promotes wound healing, increases production of collagen, rapid maturation of wound, and increases the tensile strength.44

Stem cells are found in very low amounts among the nucleated cells from the bone marrow and even lesser amounts in the peripheral blood. Fibrocytes originate in bone marrow45 and are found in peripheral blood, wounds, and tissue remodeling.46 A recent study of peripheral blood demonstrated that fibrocytes are able to proliferate cells, and induce re-epithelialization and angiogenesis in a diabetic mouse.17

Fat tissues contain multipotent cells, with similar wound healing effects of BMMSCs, stimulating human dermal fibroblasts.47 They have the capacity to differentiate into adipogenic, chondrogenic, myogenic, and osteogenic cell lineage when cultured in vitro with similar cell surface cluster of differentiation antigens.48, 49 ADSCs are obtained from either liposuction procedure or solid fat tissue. ADSCs are called adipose-derived regenerative cells because they contain heterogeneous inducible regenerative cells.50 ADSCs are more easily obtained from the donor sites than BMMC and are extensively proliferative ex vivo in vitro. Fat tissue plays an important role in regulating energy balance and substance metabolism, and its biologic function in terms of metabolism, hormone, and signaling are varying.51 In vitro, assay depending on the anatomic location of the donor sites, age, and gender may differ in yielding and differentiation capacity.52 ADSCs are approximately 5000 CFU-F per gram of adipose tissue whereas the estimated CFU-F per milliliter of bone marrow is 100 to 1000.53 Comparing lipoaspirate and excised adipose tissues, aspirated adipose tissue yields more preadipocytes within 60 minutes after extraction and at 24 hours storage at 4° than extracted tissue.54 Although distinction of preadipocytes from ADSCs via lipoaspiration is still unknown, it is acknowledged that preadipocytes can be used for fat-based regeneration.55 There are several reasons that ADSCs are most favorable cell sources for regeneration:

  • The lipoaspiration procedure is relatively common for surgeons.

  • ADSCs contain superior potentials to induce both angiogenesis and vasculogenesis.56

  • In vivo studies prove the efficacy and effectiveness using ADSCs.57

  • ADSCs are easily cultured and have high-affinity with three-dimensional scaffolds and other cells.58

ADSCs are available for promoting angiogenesis, secreting growth factors and cytokines, and differentiating into multiple cell types on stimuli. ADSCs can promote human dermal fibroblast proliferation by directly contacting cells and paracrine activation in re-epithelialization phase of wound healing.47 Two-dimensional gel electrophoretic gel proteomic analysis of the intracellular protein of BMMSCs and ADSCs revealed that the proteins were similar, which suggests that ADSCs can replace BMMSCs in cell therapy.59 In mice, wounds healed faster when treated with ADSCs than with normal process. In nonirradiated and locally irradiated wounds in mouse, ADSCs can be differentiated to keratinocytes and produce KGF as well as vascular endothelial growth factor (VEGF).60 ADSCs can release angiogenic factors in ischemic injury. ADSCs in acellular dermal matrix provide a framework for support of the regenerative capacity in wound healing.61 With appropriate scaffolds, ADSCs can cause regeneration and induce wound healing. ADSCs with skin substitute containing human ECM can produce subcutaneous, dermal, and epidermal regenerated tissues.62 Using clinically available human acellular dermal matrix of cadaveric donors, ADSCs demonstrated accelerated wound healing by 7 days postoperatively and microvascular endothelial phenotype for 2 weeks, indicating the direct vascular networking in tissue regeneration with no systemic distribution other than surgical engrafted sites.63

In a diabetic mouse model, noncultured excised ADSCs with commercially available bilayer artificial dermis can secrete several growth factors and cytokines for 4 days in cell culture supernatants, and histologic examination demonstrated advanced granulation tissue formation, capillary formation, and epithelialization for 2 weeks postoperatively.64

In a pig multiple full-thickness wound model, cultured ADSCs with platelet-rich plasma can enhance the wound healing process in terms of VEGF concentration in the fluid and cosmetic appearance.65 ADSCs are able to demonstrate antioxidant effect via dermal fibroblasts and keratinocytes in a paracrine manner,66 and hypoxia increases VEGF and bFGF levels as well as induces cell proliferation.67

Section snippets

Background of Adipose-Derived Regenerative Cell Therapy

Although literature emphasizes the merit and advantage of the use of ADSCs or adipose-derived regenerative cells (ADRCs) in wound healing, at present, there are few clinical applications. Autologous cultured BMMSCs are now being used to treat severe radiation injury.68 The purified autologous lipoaspirates are injected to improve radiation ulcers.69

Nagasaki University Global Strategic Center for Radiation Health Risk Control

This clinical study project is designed under Nagasaki University Global Strategic Center for Radiation Health Risk Control, which is one of the

First page preview

First page preview
Click to open first page preview

References (70)

  • C. Nie et al.

    Local delivery of adipose-derived stem cells via acellular dermal matrix as a scaffold: a new promising strategy to accelerate wound healing

    Med Hypotheses

    (2009)
  • A.M. Altman et al.

    Dermal matrix as a carrier for in vivo delivery of human adipose-derived stem cells

    Biomaterials

    (2008)
  • P. Martin

    Wound healing-aiming for perfect skin regeneration

    Science

    (1997)
  • H. Brem et al.

    Cellular and molecular basis of wound healing in diabetes

    J Clin Invest

    (2007)
  • T. Mustoe et al.

    Chronic wound pathogenesis and current treatment strategies: a unifying hypothesis

    Plast Reconstr Surg

    (2006)
  • D. Hanjaya-Putra et al.

    Vascular engineering using human embryonic stem cells

    Biotechnol Prog

    (2009)
  • J. Sorrell et al.

    Influence of adult mesenchymal stem cells on in vitro vascular formation

    Tissue Eng Part A

    (2009)
  • Q. Wu et al.

    Extracellular calcium increases CXCR4 expression on bone marrow-derived cells and enhances pro-angiogenesis therapy

    J Cell Mol Med

    (2009)
  • S. Watkins et al.

    When wound healing goes awry. A review of normal and abnormal wound healing, scar pathophysiology and therapeutics

    J Drugs Dermatol

    (2008)
  • A. Rogers et al.

    Involvement of proteolytic enzymes–plasminogen activators and matrix metalloproteinases–in the pathophysiology of pressure ulcers

    Wound Repair Regen

    (1995)
  • A.J. Boulton

    The diabetic foot: a global view

    Diabetes Metab Res Rev

    (2000)
  • M.A. Gershater et al.

    Complexity of factors related to outcome of neuropathic and neuroischaemic/ischaemic diabetic foot ulcers: a cohort study

    Diabetologia

    (2009)
  • J.E. Mogford et al.

    Adenoviral human telomerase reverse transcriptase dramatically improves ischemic wound healing without detrimental immune response in an aged rabbit model

    Hum Gene Ther

    (2006)
  • B.D. Kubiak et al.

    Peritoneal negative pressure therapy prevents multiple organ injury in a chronic porcine sepsis and ischemia/reperfusion model

    Shock

    (2010)
  • G.S. Schultz et al.

    Wound bed preparation: a systemic approach to wound management

    Wound Repair Regen

    (2003)
  • H.K. Kao et al.

    Peripheral blood fibrocytes: enhancement of wound healing by cell proliferation, re-epithelialization, contraction, and angiogenesis

    Ann Surg

    (2011)
  • C. Ligresiti et al.

    Wound bed preparation of difficult wounds: an evolution of the principles of TIME

    Int Wound J

    (2007)
  • L. Macri et al.

    Tissue engineering for cutaneous wounds: selecting the proper time and space for growth factors, cells and the extracellular matrix

    Skin Pharmacol Physiol

    (2009)
  • J.M. Smiell et al.

    Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies

    Wound Repair Regen

    (1998)
  • M.C. Robson et al.

    The safety and effect of topically applied recombinant basic fibroblast growth factor on healing of chronic pressure sores

    Ann Surg

    (1992)
  • W.A. Marston et al.

    The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial

    Diabetes Care

    (2003)
  • V. Falanga et al.

    A bilayered living skin construct (APLIGRAF) accelerates complete closure of hard-to-heal venous ulcers

    Wound Repair Regen

    (1999)
  • D.J. Anderson et al.

    Can stem cells cross lineage boundaries?

    Nat Med

    (2001)
  • P. Montanucci et al.

    New simple and rapid method for purification of mesenchymal stem cells from the human umbilical cord Wharton jelly

    Tissue Eng Part A

    (2011)
  • M.F. Pittenger et al.

    Multi-lineage potential of adult human mesenchymal stem cells

    Science

    (1999)
  • Cited by (0)

    Grant: Nagasaki University Global COE Program, “Global Strategic Center for Radiation Health Risk Control,” by the Japan Society for the Promotion of Science.

    View full text